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 Abstract 
 Objective: To assess different factors influencing adiponectinemia in obese and normal-
weight women; to identify factors associated with the variation (Δ) in adiponectinemia in 
obese women following a 6-month weight loss program, according to surgical/non-surgical 
interventions.  Methods: We studied 100 normal-weight women and 112 obese premeno-
pausal women; none of them was on any medical treatment. Women were characterized for 
anthropometrics, daily macronutrient intake, smoking status, contraceptives use, adiponectin 
as well as IL-6 and TNF-α serum concentrations.  Results: Adiponectinemia was lower in obese 
women (p < 0.001), revealing an inverse association with waist-to-hip ratio (p < 0.001; r = 
–0.335). Normal-weight women presented lower adiponectinemia among smokers (p = 0.041); 
body fat, waist-to-hip ratio, TNF-α levels, carbohydrate intake, and smoking all influence ad-
iponectinemia (r 2 = 0.436). After weight loss interventions, a significant modification in mac-
ronutrient intake occurs followed by anthropometrics decrease (chiefly after bariatric proce-
dures) and adiponectinemia increase (similar after surgical and non-surgical interventions). 
After bariatric intervention, Δ adiponectinemia was inversely correlated to Δ waist circumfer-
ence and Δ carbohydrate intake (r 2 = 0.706).  Conclusion : Anthropometrics, diet, smoking, and 
TNF-α levels all influence adiponectinemia in normal-weight women, although explaining less 
than 50% of it. In obese women, anthropometrics modestly explain adiponectinemia. Oppo-
site to non-surgical interventions, after bariatric surgery adiponectinemia increase is largely 
explained by diet composition and anthropometric changes.  
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 Introduction 
 Adipose tissue is a very dynamic and versatile endocrine organ secreting a large amount 
of bioactive molecules called adipokines  [1] . Adiponectin is one of the most abundant adipo-
kines secreted by adipocytes  [2] . It is a protein hormone that circulates in several different 
size complexes in serum. Its basic unit is a trimer which can assemble to form hexamers, and 
several of these hexamers can assemble into a high molecular weight (HMW) complex  [3] . 
Located on chromosome 3q27, a susceptibility locus for diabetes and cardiovascular disease, 
the adiponectin gene encodes a secretory protein expressed exclusively in adipose tissue  [4] . 
Some single nuclear polymorphisms of the adiponectin gene have been identified and may 
be an additional factor influencing adiponectinemia  [5, 6] . Adiponectin is the major adipokine 
with reported beneficial effects, namely anti-inflammatory and antiatherogenic properties, 
protecting endothelial cells, inhibiting the proliferation of vascular smooth muscle cells, and 
suppressing the conversion of macrophages to foam cells  [7] . Adiponectin circulating levels 
are inversely associated with insulin resistance although it is not perfectly determined if 
hypoadiponectinemia is a cause or consequence of that condition  [8, 9] . Although being a 
product of the adipose tissue, its levels have been demonstrated to be decreased in obese 
individuals. That paradoxical situation is not fully explained but seems to be related to the 
effect of other adipokines, mainly tumor necrosis factor alpha (TNF-α)  [10] . The excessive 
body fat mass, primarily at the abdominal location, would induce an increase in TNF-α which 
down-regulates adiponectin synthesis by the adipocytes  [11, 12] . The regular pattern of 
macronutrient consumption has also been described as a regulating factor for adiponectin 
circulating levels  [13, 14] . Hypoadiponectinemia is a risk factor for several pathological 
conditions  [15–17] . A strategy that decreases the amount of fat mass would be expected to 
augment the circulating levels of adiponectin  [18] . So, a therapeutic approach aimed to 
increase plasma adiponectin levels could be beneficial to prevent, control, or reverse condi-
tions such as the metabolic syndrome, type 2 diabetes, high blood pressure, and atheroscle-
rosis. 
 Although adiponectin circulating levels are reported to be inversely associated with body 
fat, we aimed to assess the influence of several anthropometric parameters, diet, smoking, use 
of oral contraceptives as well as interleukin 6 (IL-6) and TNF-α levels on total adiponectin 
circulating levels in both obese and normal-weight women. Secondarily, we intended to 
evaluate which of those parameters most closely parallel the variation of adiponectin levels 
expected to occur during weight loss programs (surgical and non-surgical interventions).
 Participants and Methods 
 Subjects 
 The obese group consisted of 112 obese Caucasian premenopausal women, which attended the obesity 
outpatient clinic at the Curry Cabral Hospital – C.H.L.C. (Lisbon, Portugal). Their age ranged from 18 to 50 
years, and their BMI was  ≥ 30 kg/m 2 . All of them referred a less than 10% variation of their body weight in 
the previous year.
 The control (normal-weight) group consisted on 100 Caucasian premenopausal women who either 
attended to a routine health check or belonged to the health care staff of Curry Cabral Hospital – C.H.L.C. Their 
age was between 18 and 50 years, and their BMI ranged from 18.5 to 24.9 kg/m 2 ; all of them referred less 
than 10% variation of their body weight in the previous year. 
 Although all women, obese and normal-weight, were premenopausal, none was pregnant or had been 
pregnant in the precedent 12 months. We considered only women who reported no previous diagnosis of 
any acute/chronic health condition (except obesity for the obese group). No woman was on any pharmaco-
logical regimen (except for oral contraceptives) or took any sporadic drug in the previous 7 days.
 Obese women entered in a weight loss program and were re-assessed after a 6-month follow-up.
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 The study was conducted following the approval of the institutional scientific and ethical boards 
according to the standards of the Declaration of Helsinki. Additionally, an informed consent was signed by 
all participants.
 Clinical Evaluation 
 Each woman was characterized for total body weight, BMI, waist and hip circumferences, and for their 
ratio (waist-to-hip ratio). The body fat mass (absolute value and fat mass percentage of total body weight) 
was assessed by bioelectrical impedance (Tanita TBF-300A ® , Tanita Europe B.V., Hoofddorp, the Nether-
lands). 
 Blood pressure was assessed as the mean of two determinations at the left arm with a 5-min interval 
between, following the standard recommended procedures, by the use of an electronic device (CASMED 
740 ® monitor, CAS Medical Systems Inc, Branford, CT, USA).
 Obese women were submitted to a blood pressure and anthropometric reassessment after a 6-month 
follow-up in a weight loss program.
 Dietary Evaluation 
 Each woman answered to a full detailed 24-hour food intake questionnaire, referring to an ordinary day. 
Each woman was asked to describe carefully all foods ingested considering the exact quantities. Women 
reported no significant inter-day variability. Questionnaires were analyzed in order to determine the total 
daily ingestion of carbohydrates, proteins, and fat as well as the total caloric intake.
 The same questionnaire was applied to obese women after the 6-month follow-up.
 Blood Sample Collection and Measurements 
 A venous blood sample was collected from patients and controls after overnight fasting. Serum samples 
were obtained by low-speed centrifugation, stored at a –80 ºC ultra-freezer, and thawed just before each 
assay. 
 Biochemical parameters (glucose, triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol) 
were determined by automated chemistry analyzer (Vitros ® 5.1 FS Chemistry System, Ortho-Clinical Diag-
nosis Inc, Rochester, NY, USA). Insulin concentration was assessed by a chemiluminescent immunometric 
technique (IMMULITE ® 2000 Immunoassay System, Siemens Healthcare Diagnostics, Camberley, UK). Serum 
adiponectin, IL-6, and TNF-α concentrations were measured by enzyme-linked immunosorbent assay 
following the manufacturer’s instructions (R&D Systems Inc, Minneapolis, MN, USA). Insulin resistance was 
assessed by the homeostasis model assessment (HOMA-IR) using the formula: insulin (μU/ml) × glucose 
(mg/dl) / 405.
 After the 6-month follow-up, a new fasting venous blood sample was collected from women in the obese 
group for assessment of the same parameters as in baseline.
 Statistical Analysis 
 Data are reported as mean ± SD. Comparisons between groups were made by Student’s t-test. The inter-
actions between non continuous parameters were analyzed by χ 2 test.
 Paired Student’s t-test was used to compare the change observed over time in the analyzed parameters. 
Simple associations were tested by Spearman’s r-test, and multiple regression analysis was carried out by 
the use of a forward stepwise model. A p value < 0.05 was considered statistically significant. All determina-
tions were performed using SPSS ® software, version 18.0 (IBM Corporation, Armonk, NY, USA).
 Results 
 The characterization of the obese and normal-weight groups is depicted in  table 1 . 
Although no woman reported previous comorbidities, dysglycemia was present in 25 obese 
women at baseline evaluation (based on fasting or 2-hour oral glucose tolerance test glucose 
values). Obese women with dysglycemia presented lower levels of adiponectin when 
compared with normoglycemic (5.64 vs. 7.39 μg/ml; p = 0.001).
D
ow
nl
oa
de
d 
by
: 
19
4.
21
0.
19
9.
63
 - 
8/
21
/2
01
3 
12
:5
6:
18
 P
M
127Obes Facts 2013;6:124–133
 DOI: 10.1159/000350664 
 Silva-Nunes et al.: Factors Related with Adiponectinemia in Obese and Normal-Weight 
Women and with Its Variation in Weight Loss Programs 
 www.karger.com/ofa 
© 2013 S. Karger GmbH, Freiburg
 In the normal-weight group, an inverse correlation was present for adiponectin and 
TNF-α levels (p = 0.01; r = –0.255). Only in that group, adiponectin levels were significantly 
lower (p = 0.041) in smokers ( fig. 1 ).
 Adiponectinemia showed an inverse association with almost all anthropometric param-
eters in normal-weight women, but not in obese ( table 2 ). In the normal-weight group we 
found by a stepwise analysis that a greater adjusted r 2 (0.436) was achieved if we considered 
a combination of five parameters: body fat percentage, waist-to-hip ratio, daily intake of 
carbohydrates, smoking, and TNF-α circulating levels.
 From the total group of obese women, 96 (85.7%) accomplished the 6-month reas-
sessment. All of those women received appropriate lifestyle intervention. A 1,200 kcal/day 
hypolipidic, hypoglucidic diet was prescribed, and dietetic counseling was given monthly. An 
increase or decrease of ±200 kcal/day could be advised according to anthropometric evolution 
registered in the previous month. Due to the differences in the size of the gastric pouch, in 
women submitted to bariatric surgery a further decrease in food intake down to 800
kcal/day could be necessary. Every woman was advised to perform a regular continuous 
aerobic activity of at least 150 min/week, and accomplishment was supervised every month. 
21 women were submitted to a bariatric procedure (adjustable gastric banding in 16 patients, 
sleeve gastrectomy in 4 and gastric bypass in 1). Additionally, some of the remaining 75 
women have received pharmacological intervention with anti-obesity drugs, temporarily or 
during the entire follow-up period. 
Table 1.  Baseline characterization of normal-weight and obese women groups (mean ± SD)
Normal-weight women Obese women p value
N 100 112
Age, years 34.2 ± 8.4 34.6 ± 8.3 0.702
BMI, kg/m2 21.4 ± 1.7 43.6 ± 7.9 <0.001
Total body weight, kg 56.0 ± 5.3 111.4 ± 21.3 <0.001
Total body fat, kg 14.3 ± 3.6 53.9 ± 14.8 <0.001
Percentage of body fat, % 25.3 ± 4.7 47.7 ± 5.1 <0.001
Waist circumference, cm 71.7 ± 5.8 117.5 ± 15.1 <0.001
Hip circumference, cm 97.4 ± 4.5 134.4 ± 13.3 <0.001
Waist-to-hip ratio 0.74 ± 0.05 0.88 ± 0.07 <0.001
Adiponectin, μg/ml 11.9 ± 5.09 6.89 ± 3.21 <0.001
IL-6, pg/ml 1.41 ± 1.4 2.43 ± 1.67 <0.001
TNF-α, pg/ml 1.30 ± 0.78 1.39 ± 0.88 0.445
Systolic blood pressure, mm Hg 108.9 ± 11.7 124.4 ± 16.3 <0.001
Diastolic blood pressure, mm Hg 69.2 ± 9.4 79.5 ± 10.3 <0.001
Glucose, mg/dl 81.1 ± 7.2 93.4 ± 28.6 <0.001
Insulin, μUI/ml 6.0 ± 3.8 17.6 ± 11.2 <0.001
HOMA-IR 1.21 ± 0.76 4.28 ± 3.50 <0.001
HbA1c, % 5.3 ± 0.3 5.6 ± 0.8 <0.001
Total cholesterol, mg/dl 173.6 ± 28.3 187.6 ± 32.8 0.001
LDL-cholesterol, mg/dl 103.7 ± 26.9 120.2 ± 27.1 <0.001
HDL-cholesterol, mg/dl 66.3 ± 13.8 50.9 ± 11.5 <0.001
Triglycerides, mg/dl 79.0 ± 29.1 119.1 ± 76.9 <0.001
High-sensitivity C reactive protein, mg/dl 0.22 ± 0.31 0.96 ± 0.76 <0.001
Total daily caloric intake, kcal 1,703 ± 370 1,610 ± 564 0.194
Daily intake of carbohydrates, g 208.7 ± 67.0 185.0 ± 69.1 0.023
Daily intake of proteins, g 79.7 ± 18.3 76.0 ± 23.4 0.256
Daily intake of fat, g 61.1 ± 16.1 62.8 ± 27.2 0.602
Women on oral contraceptives, % 51.0 46.4 0.506
Active smoker, % 34.0 11.6 <0.001
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 After 6 months of weight loss interventions, a significant increase in adiponectin circu-
lating levels was registered in women both on surgical and non-surgical interventions ( fig. 2 ). 
 Besides that adiponectin variation, a significant decrease in anthropometric parameters 
and a variation in diet macronutrients consumption were observed in both groups of inter-
vention ( table 3 ).
 After adjustment to the baseline values, the variation in anthropometrics was more 
pronounced in those submitted to bariatric surgery (p < 0.001 for decreases in body weight 
and body fat percentage; p = 0.001 for total fat and hip circumference; p = 0.003 for waist 
circumference; p = 0.027 for waist-to-hip ratio), but there is no significant difference in adipo-
nectin variation between both types of intervention. No difference was found in the distri-
bution of dysglycemic women between those submitted to surgical and those receiving non-
surgical interventions (23.8 vs. 27.3%). The percentage of women achieving a  ≥ 10% weight 
reduction was more significant (p < 0.001) in those submitted to bariatric surgery compared 
 Fig. 1. Adiponectin levels in obese 
and normal-weight women ac-
cording to smoking status. 
Table 2.  Association between adiponectin circulating levels and anthropometric parameters in normal-
weight and obese women at baseline
Normal-weight women  Obese women
p r  p r
BMI, kg/m2 0.001 –0.316 0.526 –0.061
Total body weight, kg 0.023 –0.228 0.495 –0.065
Total body fat, kg <0.001 –0.406 0.354 –0.088
Body fat percentage, % <0.001 –0.439 0.317 –0.095
Waist circumference, cm <0.001 –0.408 0.029 –0.207
Hip circumference, cm 0.259 –0.114 0.881 0.014
Waist-to-hip ratio <0.001 –0.362 <0.001 –0.335
 The p and r were obtained by Spearman analysis.
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with those in the non-surgical group (66.7 vs. 16.9%). Only in those submitted to bariatric 
surgery, a significant difference (p = 0.03) in adiponectin level increase was evident whether 
or not a  ≥ 10% weight reduction was achieved. 
 In women submitted to a bariatric approach, an inverse correlation was observed 
between the absolute variation of adiponectin levels and the absolute variation in carbohy-
drate intake (p = 0.019; r = –0.791) as well as the absolute variation in waist circumference 
(p = 0.005; r = –0.59); by linear regression analysis considering both parameters, we obtained 
an adjusted r 2 = 0.706. If we consider the percentage variation of adiponectin circulating 
levels, a similar inverse association is present with the percentage variation in carbohydrate 
Fig. 2. Variation in adiponectin 
circulating levels of obese women 
after 6 months in weight loss pro-
grams, according to surgical or 
non-surgical interventions.
Table 3.  Variation of parameters after 6 months, in women on surgical and non-surgical interventions
Women on bariatric surgery 
(n = 21)
Women on non-surgical interven tions 
(n = 75)
mean baseline 
values
mean month 6 
values
p  mean baseline 
values
mean month 6 
values
p
BMI, kg/m2 46.5 39.2 <0.001 43.2 41.5 <0.001
Total body weight, kg 116.9 98.4 <0.001 109.9 105.6 <0.001
Total body fat, kg 57.5 43.5 <0.001 52.9 49.7 <0.001
Percentage of body fat, % 48.6 43.6 <0.001 47.6 46.5 0.008
Waist circumference, cm 122.5 108.8 <0.001 116.7 113.6 <0.001
Hip circumference, cm 138.0 126.4 <0.001 134.0 130.6 <0.001
Waist-to-hip ratio 0.89 0.86 0.032 0.87 0.87 0.758
Adiponectin, μg/ml 6.91 9.21 0.002 7.06 8.51 <0.001
IL-6, pg/ml 2.29 2.72 0.517 2.51 2.93 0.151
TNF-α, pg/ml 1.35 1.91 0.128 1.33 2.02 0.22
Total daily caloric intake, kcal 1749 1064 0.004 1635 1359 0.002
Daily intake of carbohydrates, g 199.0 131.2 0.02 187.7 164.6 0.03
Daily intake of proteins, g 82.5 58.6 0.025 78.2 67.4 0.02
Daily intake of fat, g 69.2 33.9 0.001 63.5 47.9 <0.001
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intake (p < 0.001; r = –0.835) and waist circumference (p = 0.006; r = –0.56). An adjusted
r 2 = 0.856 is obtained by linear regression analysis taking into account these two parameters 
for the percentage of adiponectinemia variation.
 Discussion 
 Adiponectin is a very important adipokine for metabolic and cardiovascular protection. 
Every intervention that results in an increase in adiponectin circulating levels is expected to 
induce a positive health increment  [19, 20] . In accordance with previous data, we found lower 
levels of adiponectin in the obese women and, in this group, in those who were diagnosed 
with dysglycemia  [21] . 
 Inconsistent to what is usually reported  [22, 23] , we found no difference in TNF-α or IL-6 
between obese and normal-weight women. Although being obese, the women in the obese 
group entered the study with no other known comorbidity. Perhaps that could explain the 
absence of significantly higher levels of these two adipokines. Another explanation could be 
related to caloric and macronutrients intake  [24] . The authors are aware of the accuracy limi-
tations of a food questionnaire based on a single day. However, the food intake descriptions 
were carefully detailed. No difference was seen for caloric intake between groups, and normal-
weight women had even reported a higher daily intake of carbohydrates than obese women. 
Moreover, no association was found between carbohydrate intake and IL-6 or TNF-α circu-
lating levels. Obviously, once we are based in self-reported data, it is possible that some bias 
exist between data from the food intake questionnaire and what is the regular ingestion for 
each participant. 
 In normal-weight women, smoking has a deleterious effect on adiponectin circulating 
levels which is in accordance to previous data  [25] . However, this is not observed in the obese 
group, perhaps because the prevalence of smokers is far less than in the control group. In this 
group, TNF-α circulating levels are inversely associated with adiponectinemia which is in 
accordance with the effect of adiponectin gene down-regulation by TNF-α  [11] . The fact that 
this phenomenon does not occur in the obese group is unexpected and could not be explained 
by the parameters considered in this study.
 Abdominal fat mass, in obese women, and all anthropometric parameters (except hip 
circumference), in normal-weight women show an inverse association with adiponectin 
circulating levels in accordance to previous data  [26] . Opposite to obese women whose 
abdominal fat mass parameters explain about 10% of adiponectinemia, in normal-weight 
women anthropometrics, daily intake of carbohydrates, smoking, and TNF-α circulating 
levels explain nearly 50% of adiponectin circulating levels. Therefore, the regulation of total 
adiponectin levels is slightly explained by the parameters considered in this study. Although 
there is an association between the total and the HMW form of adiponectin, perhaps, if HMW 
adiponectin is considered, a more consistent explanation for the regulation of its circulating 
levels could be found  [27, 28] . 
 Bariatric surgery is more efficacious for weight loss than non-surgical interventions, 
especially in severely obese patients  [29] . This conclusion was also drawn from this study, 
with a more pronounced decrease for all anthropometric parameters in those submitted to a 
bariatric intervention than in those on non-surgical approaches.
 It has been described that a significant weight loss can decrease pro-inflammatory 
cytokine levels, namely TNF-α and IL-6  [30] . However, in this study no difference was regis-
tered for the circulating levels of those two cytokines after weight loss interventions, as 
shown by others  [31] . This finding could not be explained by the variation observed in anthro-
pometrics or in daily caloric intake or macronutrient content variations. 
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 As described in the literature, an increase in adiponectin circulating levels was observed 
with weight loss interventions  [32] . Although a significantly greater reduction in anthropo-
metrics occur in those women on a bariatric approach, the increase in adiponectin circulating 
levels showed no difference between surgical and non-surgical weight loss interventions. In 
obese women on non-surgical interventions, the variation observed in adiponectin circu-
lating levels shows no parallelism with the variation registered in the parameters considered. 
However, in those submitted to a bariatric procedure, a parallelism is already evident with 
the variation observed in anthropometrics and carbohydrate intake; that explains more than 
two thirds of the variation observed in adiponectinemia. In concordance to previous data, it 
seems necessary that a significant amelioration in anthropometrics occur in order to induce 
a significant change in adiponectinemia  [33] . Women submitted to the bariatric procedures 
were more successful in achieving a more than 10% weight loss after 6 months (66.7 vs. 
16.9%). Considering the bariatric group, those who have achieved that weight loss had a more 
pronounced increase in adiponectinemia. Although no significant difference in the variation 
of carbohydrate intake is seen between surgical and non-surgical groups, in the group 
submitted to bariatric surgery the variation that occurred in carbohydrate intake is the main 
determinant of adiponectinemia variation (independently from the subsequent variation in 
anthropometrics). This finding highlights the role of diet’s macronutrient composition on the 
adipokines’ profile of obese patients independently from its known effect on the regulation 
of body fat mass. 
 Conclusion 
 There is an inverse association between circulating adiponectin and anthropometric 
parameters both in obese and normal-weight women. Dysglycemia was associated with 
lower adiponectin levels in the obese. Smoking is a deleterious conditioning factor for adipo-
nectinemia in normal-weight women. Although there is  evidence that anthropometric param-
eters, smoking, daily carbohydrate intake, and TNF-α levels all influence adiponectinemia, 
they explain less than 50% of total adiponectin concentration in normal-weight women. In 
obese women, adiponectin is minimally associated with those factors, and anthropometrics 
(mostly the pattern of fat distribution) explain less than 10% of its circulating levels. Although 
an increase in adiponectin circulating levels occurs after surgical and non-surgical weight loss 
interventions, only in women submitted to bariatric surgery (those with a more pronounced 
reduction in anthropometric parameters) an inverse parallelism of adiponectinemia vari-
ation with diet composition and anthropometric changes is evident. Taken together, the 
changes in those two parameters observed after 6 months largely explain the variation in 
adiponectin circulating levels registered in that group.
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